

Biotinylated Anti-Trastuzumab Antibody, Mouse IgG1 (6F2F7-2)

Catalog # TRA-BLY5b



Source

Biotinylated Anti-Trastuzumab Antibody, Mouse IgG1 (6F2F7-2) is a Mouse monoclonal antibody recombinantly expressed from HEK293 cells.

Clone

6F2F7-2

Species

Mouse

Isotype

Mouse IgG1 | Mouse Kappa

Conjugate

Biotin

Antibody Type

Recombinant Monoclonal

Specificity

This product is a specific antibody specifically reacts with Trastuzumab ADA.

Application

Application	Recommended Usage
ELISA	0.5-125 ng/mL

Purity

>90% as determined by SDS-PAGE.

Purification

Protein A purified / Protein G purified

Formulation

Lyophilized from 0.22 μ m filtered solution in 50 mM Tris, 150 mM NaCl, pH7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.

SDS-PAGE



Biotinylated Anti-Trastuzumab Antibody, Mouse IgG1 (6F2F7-2) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue.

The purity of the protein is greater than 90% (With [Star Ribbon Pre-stained Protein Marker](#)).

Bioactivity-ELISA

Discounts, Gifts,
and more!




Biotinylated Anti-Trastuzumab Antibody, Mouse IgG1 (6F2F7-2)

Catalog # TRA-BLY5b



BIOSYSTEMS
Acro
Surprise Inside!



Immobilized Trastuzumab Biosimilar at 1 µg/mL (100 µL/well) can bind Biotinylated Anti-Trastuzumab Antibody, Mouse IgG1 (6F2F7-2) (Cat. No. TRA-BLY5b) with a linear range of 0.5-16 ng/mL (QC tested).

Background

Trastuzumab, is a monoclonal antibody used to treat breast cancer. Specifically it is used for breast cancer that is HER2 receptor positive. Trastuzumab works by binding to the HER2 receptor and slowing down cell duplication. Trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay ($K_d = 5$ nM) to the extracellular domain of the human epidermal growth factor receptor protein.

Clinical and Translational Updates

Discounts, Gifts,
and more!



www.acrobiosystems.com

2/10/2025